D. Navia et al., IS THE INTERNAL THORACIC ARTERY THE CONDUIT OF CHOICE TO REPLACE A STENOTIC VEIN GRAFT, The Annals of thoracic surgery, 57(1), 1994, pp. 40-44
Reoperative coronary artery bypass grafting secondary to saphenous vei
n graft (SVG) stenosis is a mushrooming problem. The internal thoracic
artery graft (ITA) provides superior long-term patency, but its now i
s limited and may be inadequate to meet large myocardial demands. To e
valuate the efficacy of the ITA as a replacement conduit for a stenoti
c SVG, 387 consecutive patients undergoing reoperative bypass grafting
from 1985 to 1990 with a stenotic SVG to a totally obstructed left an
terior descending coronary artery (LAD) were analyzed. The patients we
re divided into four groups according to the management of the previou
sly placed SVG. Group I (n = 155) underwent graft replacement with a n
ew SVG. Group II (n = 90) received an ITA with the old SVG left intact
. In group III (n = 37), an ITA was placed to the LAD with an SVG to t
he diagonal (old graft interrupted). Group IV (n = 104) had an ITA onl
y to the LAD (old graft interrupted). There were 14 deaths (3.6%). Mor
tality rate was 7.9% for group IV and 2.1% for groups I through III (p
= 0.01). Multivariate analyses identified advancing age (p = 0.001),
ITA only (p = 0.001), and female sex (p = 0.04) as independent predict
ors of operative mortality. Evidence of hypoperfusion in the distribut
ion of the LAD was present in 19 patients, all of whom were in group I
V (18.9%). Predictors of hypoperfusion were moderate/severe left ventr
icular function (p = 0.02) and ITA to the LAD with interruption of the
old graft (p = 0.0001), Hypoperfusion syndrome was treated with a new
SVG to the LAD in 11 patients, and all but I survived; 8 were treated
with an intraaortic balloon pump, for a 63% mortality (p = 0.01). We
conclude that replacing a stenotic SVG to a totally occluded LAD with
an ITA is associated with increased mortality and increased incidence
of hypoperfusion syndrome. Hypoperfusion syndrome is best treated with
supplemental vein grafting.